Rancho Cordova, CA, March 20, 2015 -- SureClinical Inc., an industry-leader in collaborative cloud health sciences applications, announced today a strategic partnership with Triumph Consultancy Services to broaden its eTMF service delivery portfolio. With offices in London, UK, and Raleigh, USA, Triumph is well positioned to provide SureClinical’s growing global customer base with specialized implementation and validation services.
Triumph has been operating for 13 years and has gained significant experience with both Pharma and CRO companies, across small, medium and large organizations. Triumph uses its wealth of clinical knowledge and experience to ensure each project is optimized to the needs of the customer and is delivered efficiently and effectively. Triumph provides both strategic and operational services around technology selection, process reengineering, organizational change management, training delivery, regulatory compliance management, and key performance metric (KPIs) study analysis.
“We are thrilled to partner with Triumph. Their consultative approach to service engagements, ensuring the needs of the customer are put first, as well as their solid track record in clinical system implementation is impressive. Clients can be assured of the very best guidance in both implementing SureClinical eTMF as well as integrating the solution with existing clinical systems.” said Chris Ibell, Chief Strategy Officer and President SureClinical Europe. “Like Triumph, SureClinical is committed to providing a best-in-class cloud eTMF that is immediately accessible to sponsors and their CROs, thereby improving study ROI. Triumph delivers a range of modularized, portfolio services that will ensure a successful implementation of SureClinical eTMF, deployed on a global, FDA and EC-compliant Certified Cloud™."
“We are excited to include the SureClinical Cloud eTMF within our technology services portfolio,” said Duncan Hall, CEO of Triumph. "SureClinical is on the forefront of delivering electronic Trial Master File capture, completion, and digital signing with the latest cloud and mobile technologies. With the majority of clinical regulatory documents still captured on paper, we see a great opportunity to provide SureClinical customers with Triumph’s best practice processes and training accelerators when transitioning their Trial Master File processes to the cloud."
SureClinical eTMF Cloud – Shred the Paper Mountain (TM)
SureClinical’s SureWorkflow and patent-pending high trust digital signing is part of an integrated solution, enabling clinical trial sponsors, CRO’s, investigators and stakeholders to collaborate, complete and Esign documents through automated workflows, eliminating paper at its origin. CRO’s, sponsors, and investigators can readily and securely sign documents from any connected mobile device, anywhere in the world without opening ports in firewalls or requiring federation of security. Moreover, since it is Cloud, SureClinical customers can activate studies within minutes delivering scale-up and scale-down flexibility based on need, without having to invest in underused on premise infrastructure or software. SureClinical eTMF Cloud automates and streamlines clinical processes, eliminates paper, which is good for the customer, environment, industry, and the customer’s bottom-line.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.